SPRR2A and neoplasm: A1–mIL-12 monotherapy mice or those receiving A1–mIL-12 in combination with anti-PD1 antibody (aPD1) experienced a significant extension in overall survival compared to mice treated with A1-ZsGreen or Eco–mIL-12 virus, underscoring that specific delivery of the therapeutic cargo to tumor-specific T cells was critical for therapeutic benefit (Fig. 5, B and C).